RARE
Ultragenyx Pharmaceutical Inc.
There isn't enough reported data to score RARE yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
RARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RARE's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
RARE PE Valuation
RARE has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 9.8x next year's earnings.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
RARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RARE has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
RARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.67 | — |
| Q3 2026 | -$5.18 | +$0.71 |
| Q2 2026 | -$5.83 | -$0.35 |
| Q1 2026 | -$6.10 | -$0.27 |
| Q4 2025 | -$5.83 | +$0.46 |
| Q3 2025 | -$5.89 | +$0.50 |
| Q2 2025 | -$5.48 | +$1.74 |
| Q1 2025 | -$5.83 | +$2.12 |
| Q4 2024 | -$6.29 | +$1.96 |
RARE is still losing money, but less than at its worst: $5.18 per share over the past year, against $10.26 at its worst in early 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over RARE on earnings quality, reporting a profit while its opponent remains loss making.
RARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $173M | +8.2% |
| Q2 2026 | $214M | +29% |
| Q1 2026 | $136M | -2.4% |
| Q4 2025 | $207.3M | +26% |
| Q3 2025 | $159.9M | +15% |
| Q2 2025 | $166.5M | +13% |
| Q1 2025 | $139.3M | +28% |
| Q4 2024 | $164.9M | +29% |
RARE has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +43 points |
| Q2 2026 | -35% | +30 points |
| Q1 2026 | -124% | -22 points |
| Q4 2025 | -55% | +20 points |
| Q3 2025 | -107% | -12 points |
| Q2 2025 | -65% | +14 points |
| Q1 2025 | -103% | +49 points |
| Q4 2024 | -74% | +22 points |
RARE's operating margin was −64% last quarter, up 43 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over RARE on profitability, with a higher operating margin.
RARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45M | +$47.7M |
| Q2 2026 | -$98M | +$12.7M |
| Q1 2026 | -$198M | -$30.2M |
| Q4 2025 | -$100.8M | -$20.6M |
| Q3 2025 | -$92.7M | -$24.1M |
| Q2 2025 | -$110.7M | -$31.8M |
| Q1 2025 | -$167.8M | +$26.1M |
| Q4 2024 | -$80.2M | +$5.3M |
RARE has burned cash in almost every quarter: −$442M over the past year, against −$451M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over RARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
RARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +200K shares |
| 1 year | +2.3% | +2.3M shares |
| 3 years | +42% | +30.4M shares |
| 5 years | +50% | +34.2M shares |
| Available history | +80% | +45.5M shares |
RARE has 102M diluted shares, up 2.3% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over RARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
RARE Net Leverage
RARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
RARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 20.3 | Neutral |
RARE's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
RARE PE vs Healthcare Sector
RARE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
RARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 5.6% above |
| 20 week MA | $21.0 | 22% below |
| 50 week MA | $23.4 | 31% below |
| 100 week MA | $29.5 | 45% below |
| 200 week MA | $37.2 | 56% below |
RARE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 56% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over RARE on trend strength, trading above more of its moving averages.
RARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43.4 | $172.9 | +298% |
| 2021 | $172.9 | $84.7 | -51% |
| 2022 | $84.7 | $43.5 | -49% |
| 2023 | $43.5 | $47.8 | +9.9% |
| 2024 | $47.8 | $43.4 | -9.2% |
| 2025 | $43.4 | $34.2 | -21% |
| 2026 YTD | $34.2 | $16.3 | -52% |
RARE's yearly returns have swung widely, from +298% in 2020 to −51% in 2021. It's down 52% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over RARE on returns for 2026, with the stronger performance.